Pranav Kumar Vemula,Yu Jing,Jody Cicolini,Hu Zhang,Bruce G Mockett,Wickliffe C Abraham,Ping Liu,Bruce G. Mockett,Wickliffe C. Abraham
Abstract:Amyloid-beta (Aβ) cleaved from amyloid precursor protein (APP) has been proposed to play a central and causative role in the aetiology of Alzheimer's disease (AD). APP<sub>swe</sub>/PSEN1<sub>dE9</sub> (APP/PS1) transgenic mice display chronic Aβ accumulation and deposition in the brain. L-arginine is a semi-essential amino acid with a number of bioactive metabolites, and altered arginine metabolism has been implicated in the pathogenesis and/or the development of AD. This study systematically investigated how arginine metabolic profiles changed in the frontal cortex, hippocampus, parahippocampal region and cerebellum of male APP/PS1 mice at 4, 9 and 17 months of age relative to their sex- and age-matched wildtype controls. Immunohistochemistry demonstrated age-related Aβ deposition in the brain. High-performance liquid chromatography and mass spectrometry revealed age-related increases in glutamine, spermidine and spermine in APP/PS1 mice in a region-specific manner. Notably, genotype-related increases in spermine were found in the frontal cortex at the 9-month age point and in the frontal cortex, hippocampus and parahippocampal region at 17 months of age. Given the existing literature indicating the role of polyamines (spermine in particular) in modulating the aggregation and toxicity of Aβ oligomers, increased spermidine and spermine levels in APP/PS1 mice may be a neuroprotective mechanism to combat Aβ toxicity. Future research is required to better understand the functional significance of these changes.
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore the changes in brain arginine metabolism with age in the APP swe/PSEN1 dE9 transgenic mouse model of Alzheimer's disease (AD). Specifically, the study aims to systematically analyze the changes in the arginine metabolism profiles in the frontal cortex, hippocampus, medial temporal lobe area and cerebellum of this mouse model at 4, 9 and 17 months of age, and compare them with the wild - type control group of the same age.
### Research Background
Alzheimer's disease is a neurodegenerative disease, and the accumulation of β - amyloid (Aβ) is considered to be one of the key factors in pathogenesis. However, in recent years, more and more studies have begun to focus on other potential mechanisms, especially those involving changes in amino acid metabolism. L - arginine, as a semi - essential amino acid, has metabolites including nitric oxide (NO), polyamines (such as spermidine and spermine), etc., and these substances play important roles in neuroprotection and neurotoxicity.
### Research Questions
1. **Age - related Aβ deposition**: Observe the Aβ deposition in the brains of APP/PS1 mice with age growth by immunohistochemistry.
2. **Changes in arginine metabolism profiles**: Use high - performance liquid chromatography (HPLC) and liquid chromatography - mass spectrometry (LC/MS) techniques to quantitatively analyze the concentration changes of L - arginine and its downstream metabolites (such as L - citrulline, L - ornithine, glutamine, glutamate, GABA, spermidine, spermine, etc.) in different brain regions.
3. **Relationship between polyamine levels and Aβ toxicity**: Explore whether the increase in polyamine (especially spermine) levels may be a neuroprotective mechanism against Aβ toxicity.
### Key Findings
- In 4 - month - old APP/PS1 mice, there is less Aβ deposition, and there is no significant difference in the arginine metabolism profile from wild - type mice.
- At 9 months of age, the spermine level in the frontal cortex of APP/PS1 mice is significantly increased.
- By 17 months of age, the spermine and spermidine levels in multiple brain regions (frontal cortex, hippocampus, medial temporal lobe area) of APP/PS1 mice are significantly increased, which may reflect the neuroprotective response with the increase in Aβ deposition.
### Conclusion
This study reveals that in the APP/PS1 mouse model, with age growth, the brain arginine metabolism profile has changed significantly, especially the increase in polyamine levels, which may be a neuroprotective mechanism against Aβ toxicity. Future studies need to further explore the functional significance of these metabolic changes and their roles in the AD pathological process.